← All trials
NCT02405676
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2015
- Primary completion
- Jun 1, 2021
- Completion date
- Dec 1, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 200
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Children's Cancer Group, ChinaLead sponsor
- Children's Cancer Group, ChinaReponsible party - principal investigator
- Shandong UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Sichuan UniversityCollaborator
- Central South UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Jiao Tong UniversityOverall official - principal investigator
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.